Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908062 · ClinicalTrials.gov registry record · Phase 3
Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study
A Phase 3 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
NCT01908062 is a Phase 3 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 51 participants.
The verdict
NCT01908062, a Phase 3 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to learn how best to treat substance use disorders in an HIV clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release naltrexone (XR-NTX) would be a feasible and acceptable treatment for HIV-infected individuals with opioid or alcohol use disorders.
Interventions
- DRUG Extended Release Naltrexone
- OTHER Treatment As usual
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01908062
The ClinicalTrials.gov registry entry for NCT01908062 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Extended Release Naltrexone is the first listed.
NCT01908062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01908062 about?
NCT01908062 is a clinical study titled "Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study". The purpose of this study is to learn how best to treat substance use disorders in an HIV clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release naltrexone (XR-NTX) would be a feasible and acceptable treatment for HIV-infected individuals with opioid or alcohol...
What is the current status of trial NCT01908062?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2014-06. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01908062?
The interventions under investigation include: Extended Release Naltrexone (DRUG), Treatment As usual (OTHER).
Who is sponsoring clinical trial NCT01908062?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.